Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm IncfiledCriticalEnanta Pharm Inc
Publication of AR126501A1publicationCriticalpatent/AR126501A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención revela compuestos de fórmula (1), y sales de uso farmacéutico aceptables del mismo: que inhiben la actividad de replicación del coronavirus. La invención se refiere además a composiciones farmacéuticas que comprenden un compuesto de fórmula (1) o una sal de uso farmacéutico aceptable del mismo, y a métodos de tratamiento o prevención de una infección por coronavirus en un sujeto que lo necesita, que comprenden administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula (1) o una sal de uso farmacéutico aceptable del mismo.The present invention discloses compounds of formula (1), and pharmaceutically acceptable salts thereof: that inhibit the replication activity of the coronavirus. The invention further relates to pharmaceutical compositions comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof, and to methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof.
ARP220101896A2020-03-312022-07-20
NEW ANTIVIRAL AGENTS DERIVED FROM SPIROPYRROLIDINE
AR126501A1
(en)
HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
COMPOUND IN GENERAL FORMULA (I) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
2- (BUTYL-1-SULFONYLAMINO) -N- [1 (R) - (6-METOXY-PYRIDIN-3-YL) -PROPYL] -BENZAMIDE, USE OF SAID COMPOUND IN THE FORM OF A MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME LEDIT COMPOSE